UA74588C2 - Method for locating compounds suitable for treatment and/or prophylaxis of obesity (variants) and use of such compounds for production of anti-obesity drugs (variants) - Google Patents
Method for locating compounds suitable for treatment and/or prophylaxis of obesity (variants) and use of such compounds for production of anti-obesity drugs (variants) Download PDFInfo
- Publication number
- UA74588C2 UA74588C2 UA2003021453A UA2003021453A UA74588C2 UA 74588 C2 UA74588 C2 UA 74588C2 UA 2003021453 A UA2003021453 A UA 2003021453A UA 2003021453 A UA2003021453 A UA 2003021453A UA 74588 C2 UA74588 C2 UA 74588C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compounds
- obesity
- treatment
- differs
- mammals
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 76
- 238000000034 method Methods 0.000 title claims abstract description 68
- 208000008589 Obesity Diseases 0.000 title claims abstract description 38
- 235000020824 obesity Nutrition 0.000 title claims abstract description 38
- 238000011282 treatment Methods 0.000 title claims abstract description 33
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 claims abstract description 27
- 102000003846 Carbonic anhydrases Human genes 0.000 claims description 41
- 108090000209 Carbonic anhydrases Proteins 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 31
- 230000002265 prevention Effects 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 24
- 230000002401 inhibitory effect Effects 0.000 claims description 21
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims description 20
- 241000282412 Homo Species 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 210000001789 adipocyte Anatomy 0.000 claims description 9
- 230000001773 anti-convulsant effect Effects 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000002207 metabolite Substances 0.000 claims description 7
- 241000283984 Rodentia Species 0.000 claims description 6
- 238000010352 biotechnological method Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 210000003494 hepatocyte Anatomy 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 229940126601 medicinal product Drugs 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 20
- 229960004394 topiramate Drugs 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000004132 lipogenesis Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical group OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013367 dietary fats Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000611750 Coregonus kiyi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 108050004689 Inhibitor of carbonic anhydrases Proteins 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100133904 Mus musculus Nrk gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 1
- 229950005098 ethoxzolamide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003165 hydrotropic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10035227A DE10035227A1 (de) | 2000-07-20 | 2000-07-20 | Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind |
| PCT/EP2001/008051 WO2002007821A1 (de) | 2000-07-20 | 2001-07-12 | Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA74588C2 true UA74588C2 (en) | 2006-01-16 |
Family
ID=7649538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003021453A UA74588C2 (en) | 2000-07-20 | 2001-12-07 | Method for locating compounds suitable for treatment and/or prophylaxis of obesity (variants) and use of such compounds for production of anti-obesity drugs (variants) |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1307262B1 (no) |
| JP (1) | JP2004504053A (no) |
| KR (1) | KR100818827B1 (no) |
| CN (1) | CN1443085B (no) |
| AR (1) | AR028730A1 (no) |
| AT (1) | ATE278441T1 (no) |
| AU (2) | AU2001277534B9 (no) |
| BR (1) | BR0112547A (no) |
| CA (1) | CA2416647A1 (no) |
| CZ (1) | CZ2003156A3 (no) |
| DE (2) | DE10035227A1 (no) |
| DZ (1) | DZ3393A1 (no) |
| ES (1) | ES2230346T3 (no) |
| HK (1) | HK1057499A1 (no) |
| HU (1) | HUP0302309A3 (no) |
| IL (2) | IL153971A0 (no) |
| MX (1) | MXPA02012907A (no) |
| NO (1) | NO20030233L (no) |
| NZ (1) | NZ523960A (no) |
| PL (1) | PL201165B1 (no) |
| PT (1) | PT1307262E (no) |
| RU (1) | RU2268721C2 (no) |
| SK (1) | SK287607B6 (no) |
| TR (1) | TR200402670T4 (no) |
| TW (1) | TWI274157B (no) |
| UA (1) | UA74588C2 (no) |
| WO (1) | WO2002007821A1 (no) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1997370B (zh) | 2004-05-19 | 2011-06-01 | 索尔瓦药物有限公司 | N-氨磺酰-n＇-芳基哌嗪类化合物在制备用于预防或治疗肥胖和相关疾病的药物中的用途 |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| KR20080012360A (ko) | 2005-05-20 | 2008-02-11 | 얀센 파마슈티카 엔.브이. | 설파미드 유도체의 제조 방법 |
| AR057570A1 (es) | 2005-11-14 | 2007-12-05 | Solvay Pharm Gmbh | Derivados de n-sulfamoil-n'-benzopiranopiperidinas espirocondensadas, composiciones farmaceuticas que los comprenden, un procedimiento para su preparacion y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por las isoenzimas anhidrasas carbonicas subtipos ii y/o |
| US8492431B2 (en) * | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| TW200812573A (en) | 2006-05-19 | 2008-03-16 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
| NO2106260T3 (no) | 2007-01-25 | 2018-05-05 | ||
| US8809385B2 (en) | 2008-06-23 | 2014-08-19 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| KR20150023405A (ko) * | 2012-05-24 | 2015-03-05 | 베바 파마슈티칼스 엘티디 | 간 기능 개선 방법 |
| CN106770611B (zh) * | 2016-12-22 | 2019-01-29 | 广西师范大学 | 一种用于细胞原位检测小分子化合物进入线粒体的方法 |
| RU2771430C1 (ru) * | 2021-09-21 | 2022-05-04 | Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) | Способ количественного определения антиконвульсантов в плазме крови больных эпилепсией |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4552897A (en) * | 1983-02-01 | 1985-11-12 | American Cyanamid Company | Salts of 1-(aminodihalophenyl)-2-aminoethanols and antilipogenic compositions prepared therefrom |
| US6288095B1 (en) * | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| JPH08502969A (ja) * | 1992-10-29 | 1996-04-02 | ジェネンテク，インコーポレイテッド | 肥満の予防または治療方法 |
| AU693478B2 (en) * | 1994-11-10 | 1998-07-02 | Metabolic Pharmaceuticals Limited | Treatment of obesity |
| CA2258893C (en) * | 1996-06-28 | 2005-06-14 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant sulfamate derivatives useful in treating obesity |
| US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
-
2000
- 2000-07-20 DE DE10035227A patent/DE10035227A1/de not_active Withdrawn
-
2001
- 2001-06-15 AR ARP010102883A patent/AR028730A1/es unknown
- 2001-07-12 AU AU2001277534A patent/AU2001277534B9/en not_active Ceased
- 2001-07-12 IL IL15397101A patent/IL153971A0/xx unknown
- 2001-07-12 AT AT01955345T patent/ATE278441T1/de active
- 2001-07-12 TR TR2004/02670T patent/TR200402670T4/xx unknown
- 2001-07-12 NZ NZ52396001A patent/NZ523960A/xx not_active IP Right Cessation
- 2001-07-12 JP JP2002513551A patent/JP2004504053A/ja active Pending
- 2001-07-12 EP EP01955345A patent/EP1307262B1/de not_active Expired - Lifetime
- 2001-07-12 PL PL363518A patent/PL201165B1/pl not_active IP Right Cessation
- 2001-07-12 PT PT01955345T patent/PT1307262E/pt unknown
- 2001-07-12 ES ES01955345T patent/ES2230346T3/es not_active Expired - Lifetime
- 2001-07-12 CZ CZ2003156A patent/CZ2003156A3/cs unknown
- 2001-07-12 CA CA002416647A patent/CA2416647A1/en not_active Abandoned
- 2001-07-12 DZ DZ013393A patent/DZ3393A1/xx active
- 2001-07-12 SK SK61-2003A patent/SK287607B6/sk not_active IP Right Cessation
- 2001-07-12 BR BR0112547-8A patent/BR0112547A/pt not_active Application Discontinuation
- 2001-07-12 DE DE50104023T patent/DE50104023D1/de not_active Expired - Lifetime
- 2001-07-12 HU HU0302309A patent/HUP0302309A3/hu unknown
- 2001-07-12 RU RU2003104803/14A patent/RU2268721C2/ru not_active IP Right Cessation
- 2001-07-12 MX MXPA02012907A patent/MXPA02012907A/es active IP Right Grant
- 2001-07-12 CN CN018129730A patent/CN1443085B/zh not_active Expired - Fee Related
- 2001-07-12 WO PCT/EP2001/008051 patent/WO2002007821A1/de active IP Right Grant
- 2001-07-12 KR KR1020037000620A patent/KR100818827B1/ko not_active IP Right Cessation
- 2001-07-12 AU AU7753401A patent/AU7753401A/xx active Pending
- 2001-07-16 TW TW090117382A patent/TWI274157B/zh not_active IP Right Cessation
- 2001-12-07 UA UA2003021453A patent/UA74588C2/uk unknown
-
2003
- 2003-01-15 IL IL153971A patent/IL153971A/en not_active IP Right Cessation
- 2003-01-17 NO NO20030233A patent/NO20030233L/no unknown
-
2004
- 2004-01-15 HK HK04100307.4A patent/HK1057499A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA74588C2 (en) | Method for locating compounds suitable for treatment and/or prophylaxis of obesity (variants) and use of such compounds for production of anti-obesity drugs (variants) | |
| Dwyer et al. | Plant and human neutrophil oxidative burst complexes contain immunologically related proteins | |
| Rigutto et al. | Activation of dual oxidases Duox1 and Duox2 | |
| Ohshima et al. | Increased nitrosamine and nitrate biosynthesis mediated by nitric oxide synthase induced in hamsters infected with liver fluke (Opisthorchis viverrini) | |
| US6946243B2 (en) | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity | |
| JP2008510723A (ja) | 血管新生の治療法 | |
| Carter et al. | Decreased urinary output of tyramine and its metabolites in depression | |
| Verdy et al. | Quantitative assessment of lactate and progerin production in normal human cutaneous cells during normal ageing: Effect of an Alaria esculenta extract | |
| EP0729356A1 (en) | Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases | |
| WO2000057871A2 (en) | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof | |
| AU2004317897B2 (en) | Activation of hypoxia-inducible gene expression | |
| Matsunaga et al. | Reactive oxygen species as a risk factor in verotoxin-1-exposed rats | |
| Van Geldre et al. | L-citrulline recycling by argininosuccinate synthetase and lyase in rat gastric fundus | |
| Julémont et al. | Recent developments in 5lipoxygenase inhibitors | |
| Neves et al. | Nitric oxide-mediated immune complex-induced prostaglandin E2 production by peripheral blood mononuclear cells of humans infected with Schistosoma mansoni | |
| KR100442322B1 (ko) | 이소시트릭산 탈수소화효소 활성 저해제를 유효성분으로포함하는 비만, 고지혈증 또는 지방간 예방 또는 치료제 | |
| JP7422388B2 (ja) | アクアポリン３の発現亢進能を有する短鎖脂肪酸 | |
| CN115837019A (zh) | α-酮戊二酸、含有α-酮戊二酸的米发酵液在制备5α-还原酶抑制剂中的用途 | |
| CN118161490A (zh) | 一种去泛素化酶抑制剂在制备预防或者治疗炎症药物中的应用 | |
| CN116139159A (zh) | 一种prdx6蛋白的抑制剂在制备改善氧化应激损伤的药物中的应用 | |
| Edgett | Regulation of SIRT1, sirt3, PGC-1α, and LRP130 in response to energetic stress in human skeletal muscle | |
| Gong et al. | Articles in PresS. J Appl Physiol (September 15, 2005). doi: 10.1152/japplphysiol. 00873.2005 | |
| Hu | Characterization of human pyruvate dehydrogenase kinase isoform 2 (PDHK2) | |
| Eschenröder et al. | ENHANCED EXPRESSION OF CARNITINE PALMITOYL TRANSFERASE-Ia (CPT-Icx) IN RAT MESANGIAL CELLS BY EXOGENOUS SECRETED PHOSPHOLIPASE А2-ПА | |
| Linnér | Noradrenergic augmentation strategies in the pharmacological treatment of depression and schizophrenia: an experimental study |